1 Division of Pulmonary and Critical Care Medicine, University of California, San Diego, La Jolla, California; and.
2 Centre de Référence de l'Hypertension Pulmonaire Sévère, Service de Pneumologie et Réanimation, Hôpital Bicetre, Université Paris-Sud, Paris, France.
Ann Am Thorac Soc. 2016 Jul;13 Suppl 3:S255-8. doi: 10.1513/AnnalsATS.201601-065AS.
In looking toward the future of chronic thromboembolic pulmonary hypertension, the following four clinical questions deserve careful consideration: (1) What is inoperable disease, and how is it defined? (2) Is there a role for targeted medical therapy in technically operable, proximal disease? (3) Where does balloon pulmonary angioplasty fit into the treatment algorithm? (4) How should we approach patients with symptomatic chronic pulmonary thromboembolism without pulmonary hypertension? The search for these answers will continue to propel this field forward. Consequently, the crossroads we find ourselves at signal opportunity and hope for future advances.
展望慢性血栓栓塞性肺动脉高压的未来,以下四个临床问题值得仔细考虑:(1)什么是不可手术的疾病,如何定义?(2)在技术上可手术的近端疾病中,靶向药物治疗是否有作用?(3)球囊肺动脉成形术在治疗方案中的位置在哪里?(4)对于没有肺动脉高压但有症状的慢性肺血栓栓塞症患者,我们应该如何处理?对这些问题的研究将继续推动该领域的发展。因此,我们所处的十字路口标志着未来取得进展的机会和希望。